ENTRADA THERAPEUTICS, INC. Earnings Per Share (Diluted)
ENTRADA THERAPEUTICS, INC. (TRDA) reported Earnings Per Share (Diluted) of -$1.01 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-08-05
- ENTRADA THERAPEUTICS, INC. earnings per share, diluted for the quarter ending 2026-06-30 was -$1.01.
- ENTRADA THERAPEUTICS, INC. earnings per share, diluted for the quarter ending 2026-03-31 was -$0.95.
- ENTRADA THERAPEUTICS, INC. earnings per share, diluted for the quarter ending 2025-12-31 was -$0.94, a 3700.57% decline year-over-year.
- ENTRADA THERAPEUTICS, INC. earnings per share, diluted for the quarter ending 2025-09-30 was -$1.06.
- ENTRADA THERAPEUTICS, INC. earnings per share, diluted for fiscal 2025 was -$3.47, a 306.55% decline from fiscal 2024.
- ENTRADA THERAPEUTICS, INC. earnings per share, diluted for fiscal 2024 was $1.68.
- ENTRADA THERAPEUTICS, INC. earnings per share, diluted for fiscal 2023 was -$0.20.
- ENTRADA THERAPEUTICS, INC. earnings per share, diluted for fiscal 2022 was -$3.02.
| Period end | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.01 10-Q · filed 2026-08-05 | -$1.96 10-Q · filed 2026-08-05 | -$2.90 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$3.97 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2026-03-31 | -$0.95 10-Q · filed 2026-05-07 | -$1.89 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$2.95 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$4.00 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2025-12-31 | -$0.94 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$2.01 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$3.05 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$3.47 10-K · filed 2026-02-26 |
| 2025-09-30 | -$1.06 10-Q · filed 2025-11-06 | -$2.11 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$2.53 10-Q · filed 2025-11-06 | -$2.48 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2025-06-30 | -$1.04 10-Q · filed 2026-08-05 | -$1.47 10-Q · filed 2026-08-05 | -$1.42 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$1.76 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2025-03-31 | -$0.42 10-Q · filed 2026-05-07 | -$0.38 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$0.73 derived: net income ÷ weighted average shares · filed 2026-08-05 | $0.62 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2024-12-31 | $0.03 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$0.31 derived: net income ÷ weighted average shares · filed 2026-02-26 | $1.06 derived: net income ÷ weighted average shares · filed 2026-02-26 | $1.68 10-K · filed 2026-02-26 |
| 2024-09-30 | -$0.35 10-Q · filed 2025-11-06 | $1.08 derived: net income ÷ weighted average shares · filed 2025-11-06 | $1.72 10-Q · filed 2025-11-06 | $1.57 derived: net income ÷ weighted average shares · filed 2025-11-06 |
| 2024-06-30 | $1.55 10-Q · filed 2025-08-06 | $2.23 10-Q · filed 2025-08-06 | $2.08 derived: net income ÷ weighted average shares · filed 2025-11-06 | $3.11 derived: net income ÷ weighted average shares · filed 2025-11-06 |
| 2024-03-31 | $0.68 10-Q · filed 2025-05-08 | $0.44 derived: net income ÷ weighted average shares · filed 2025-11-06 | $1.50 derived: net income ÷ weighted average shares · filed 2025-11-06 | $0.71 derived: net income ÷ weighted average shares · filed 2025-11-06 |
| 2023-12-31 | -$0.33 derived: net income ÷ weighted average shares · filed 2025-02-27 | $0.81 derived: net income ÷ weighted average shares · filed 2025-02-27 | -$0.00 derived: net income ÷ weighted average shares · filed 2025-02-27 | -$0.20 10-K · filed 2025-02-27 |
| 2023-09-30 | $1.02 10-Q · filed 2024-11-05 | $0.28 derived: net income ÷ weighted average shares · filed 2024-11-05 | $0.08 10-Q · filed 2024-11-05 | -$0.66 derived: net income ÷ weighted average shares · filed 2024-11-05 |
| 2023-06-30 | -$0.78 10-Q · filed 2024-08-13 | -$0.99 10-Q · filed 2024-08-13 | -$1.77 derived: net income ÷ weighted average shares · filed 2024-11-05 | -$2.57 derived: net income ÷ weighted average shares · filed 2024-11-05 |
| 2023-03-31 | -$0.21 10-Q · filed 2024-05-07 | -$0.98 derived: net income ÷ weighted average shares · filed 2024-11-05 | -$1.78 derived: net income ÷ weighted average shares · filed 2024-11-05 | -$2.52 derived: net income ÷ weighted average shares · filed 2024-11-05 |
| 2022-12-31 | -$0.79 derived: net income ÷ weighted average shares · filed 2024-03-13 | -$1.59 derived: net income ÷ weighted average shares · filed 2024-03-13 | -$2.33 derived: net income ÷ weighted average shares · filed 2024-03-13 | -$3.02 10-K · filed 2024-03-13 |
| 2022-09-30 | -$0.80 10-Q · filed 2023-11-07 | -$1.54 derived: net income ÷ weighted average shares · filed 2023-11-07 | -$2.24 10-Q · filed 2023-11-07 | -$3.08 derived: net income ÷ weighted average shares · filed 2023-11-07 |
| 2022-06-30 | -$0.74 10-Q · filed 2023-08-08 | -$1.43 10-Q · filed 2023-08-08 | -$2.27 derived: net income ÷ weighted average shares · filed 2023-11-07 | -$3.66 derived: net income ÷ weighted average shares · filed 2023-11-07 |
| 2022-03-31 | -$0.69 10-Q · filed 2023-05-10 | -$1.54 derived: net income ÷ weighted average shares · filed 2023-11-07 | -$3.05 derived: net income ÷ weighted average shares · filed 2023-11-07 | -$4.68 derived: net income ÷ weighted average shares · filed 2023-11-07 |
| 2021-12-31 | -$0.88 derived: net income ÷ weighted average shares · filed 2023-03-06 | -$2.92 derived: net income ÷ weighted average shares · filed 2023-03-06 | -$5.39 derived: net income ÷ weighted average shares · filed 2023-03-06 | -$8.16 10-K · filed 2023-03-06 |
| 2021-09-30 | -$9.78 10-Q · filed 2022-11-07 | -$17.47 derived: net income ÷ weighted average shares · filed 2022-11-07 | -$24.18 10-Q · filed 2022-11-07 | -$31.68 derived: net income ÷ weighted average shares · filed 2022-11-07 |
| 2021-06-30 | -$7.56 10-Q · filed 2022-08-11 | -$14.16 10-Q · filed 2022-08-11 | -$21.56 derived: net income ÷ weighted average shares · filed 2022-11-07 | -$27.76 derived: net income ÷ weighted average shares · filed 2022-11-07 |
| 2021-03-31 | -$6.67 10-Q · filed 2022-05-12 | -$13.97 derived: net income ÷ weighted average shares · filed 2022-11-07 | -$20.14 derived: net income ÷ weighted average shares · filed 2022-11-07 | |
| 2020-12-31 | -$7.32 derived: net income ÷ weighted average shares · filed 2022-03-15 | -$13.48 derived: net income ÷ weighted average shares · filed 2022-03-15 | -$24.00 10-K · filed 2022-03-15 | |
| 2020-09-30 | -$6.13 10-Q · filed 2021-12-09 | -$16.55 10-Q · filed 2021-12-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |